← Evidence map

ArticleThrombosis journal2026

Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study.

Juan Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study. | OpenQuestion